Adalimumab - An effective and promising treatment for patients with fistulizing Crohn's disease: A case series

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Kouklakis, George ^a   Efremidou, Eleni I ^a   Zezos, Peter ^a   Liratzopoulos, Nikolaos ^a   Souftas, Vassilios D ^a   Gatopoulou, Anthia ^a   Simopoulos, Konstantinos ^a   Manolas, Konstantinos J ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PREDNISOLONE;

ABSENCE OF SIDE EFFECTS; ACUTE APPENDICITIS; ADULT; ANASTOMOSIS; APPENDECTOMY; ARTICLE; CASE REPORT; COLONOSCOPY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYANOSIS; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL; FEMALE; FISTULIZING CROHN DISEASE; GASTROINTESTINAL ENDOSCOPY; HEPATITIS; HISTOPATHOLOGY; HOARSENESS; HUMAN; INTESTINE FISTULA; INTESTINE ULCER; LAPAROTOMY; LEUKOCYTE; LYMPHOCYTE; MAINTENANCE THERAPY; MALE; NEUTROPHIL; PANCREATITIS; PLASMA CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REMISSION; SMALL INTESTINE OBSTRUCTION; TACHYCARDIA; THORAX DRAINAGE; TOTAL PARENTERAL NUTRITION;

EID: 79952698916     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-109     Document Type: Article

References (15)

1. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. DA Schwartz EV Loftus Jr WJ Tremaine R Panaccione WS Harmsen AR Zinsmeister WJ Sandborn, Gastroenterology 2002 122 4 875 880 10.1053/gast.2002.32362 11910338 (Pubitemid 34267269)
2. Infliximab maintenance therapy for fistulizing Crohn's disease. BE Sands FH Anderson CN Bernstein WY Chey BG Feagan RN Fedorak MA Kamm JR Korzenik BA Lashner JE Onken D Rachmilewitz P Rutgeerts G Wild DC Wolf PA Marsters SB Travers MA Blank SJ van Deventer, N Engl J Med 2004 350 876 885 10.1056/NEJMoa030815 14985485 (Pubitemid 38252535)
3. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. SB Hanauer WJ Sandborn P Rutgeerts RN Fedorak M Lukas D MacIntosh R Panaccione D Wolf P Pollack, Gastroenterology 2006 130 323 333 10.1053/j.gastro.2005.11.030 16472588
4. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. JF Colombel WJ Sandborn P Rutgeerts R Enns SB Hanauer R Panaccione S Schreiber D Byczkowski J Li JD Kent PF Pollack, Gastroenterology 2007 132 52 65 10.1053/j.gastro.2006.11.041 17241859 (Pubitemid 46108762)
5. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. WJ Sandborn SB Hanauer P Rutgeerts RN Fedorak M Lukas DG MacIntosh R Panaccione D Wolf JD Kent B Bittle J Li PF Pollack, Gut 2007 56 1232 1239 10.1136/gut.2006.106781 17299059 (Pubitemid 47300424)
6. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. J Hinojosa F Gomollán S García G Bastida JL Cabriada C Saro D Ceballos M Pẽate MA Gassull Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis, Aliment Pharmacol Ther 2007 25 409 418 10.1111/j.1365-2036.2006.03232.x 17269996 (Pubitemid 46184454)
7. Adalimumab for the treatment of fistulas in patients with Crohn's disease. JF Colombel DA Schwartz WJ Sandborn MA Kamm G D'Haens P Rutgeerts R Enns R Panaccione S Schreiber J Li JD Kent KG Lomax PF Pollack, Gut 2009 58 940 948 10.1136/gut.2008.159251 19201775
8. Efficacy and safety of tumor necrosis factor antagonists in crohn's disease: meta-analysis of placebo-controlled trials. L Peyrin-Biroulet P Deltenre N de Suray J Branche WJ Sandborn JF Colombel, Clin Gastroenterol Hepatol 2008 6 644 653 10.1016/j.cgh.2008.03.014 18550004 (Pubitemid 351783447)
9. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. F Hadziselimovic, J Pediatr Gastroenterol Nutr 2008 46 208 211 10.1097/MPG.0b013e318124504b 18223382 (Pubitemid 351161129)
10. Surgical treatment of complex enterocutaneous fistulas in IBD patients using human acellular dermal matrix. T Taner RR Cima DW Larson EJ Dozois JH Pemberton BG Wolff, Inflamm Bowel Dis 2009 15 8 1208 1212 10.1002/ibd.20882 19170192
11. Treatment of enterocutaneous fistula in Crohn's Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. D Garcia-Olmo D Herreros M Pascual I Pascual P De-La-Quintana J Trebol M Garcia-Arranz, Int J Colorectal Dis 2009 24 1 27 30 10.1007/s00384-008-0559-0 18696086
12. Current management of enterocutaneous fistula. AR Evenson JE Fischer, J Gastrointest Surg 2006 10 3 455 464 10.1016/j.gassur.2005.08.001 16504896 (Pubitemid 43303845)
13. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. JL Martinez E Luque-Leon J Mier R Blanco-Benavides F Robledo, World J Surg 2008 32 436 443 10.1007/s00268-007-9304-z 18057983
14. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas. RG Visschers SW Olde Damink B Winkens PB Soeters WG Van Gemert, World J Surg 2008 32 445 453 10.1007/s00268-007-9371-1 18175171
15. An 11-year experience of enterocutaneous fistula. P Hollington J Mawdsley W Lim SM Gabe A Forbes AJ Windsor, Br J Surg 2004 91 1646 1651 10.1002/bjs.4788 15505866 (Pubitemid 39619931)